Menu
Search
|

Menu

Close
X

Tonghua Dongbao Pharmaceutical Co Ltd 600867.SS (Shanghai Stock Exchange)

25.31 CNY
-0.01 (-0.04%)
As of Jul 19
chart
Previous Close 25.32
Open 25.36
Volume 13,782,039
3m Avg Volume 17,536,275
Today’s High 25.69
Today’s Low 24.92
52 Week High 27.51
52 Week Low 13.88
Shares Outstanding (mil) 2,053.56
Market Capitalization (mil) 51,975.50
Forward P/E 48.09
Dividend (Yield %) 0.17 ( 0.66 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 15 analysts

KEY STATS

Revenue (mm, CNY)
FY18
719
FY17
2,545
FY16
2,040
FY15
1,669
EPS (CNY)
FY18
0.160
FY17
0.490
FY16
0.390
FY15
0.302
*Note: Units in Millions of Renminbi
**Note: Units in Renminbi

KEY RATIOS

Price to Earnings (TTM)
vs sector
48.09
33.05
Price to Sales (TTM)
vs sector
19.26
8.10
Price to Book (MRQ)
vs sector
9.02
4.20
Price to Cash Flow (TTM)
vs sector
--
22.23
Total Debt to Equity (MRQ)
vs sector
0.00
17.32
LT Debt to Equity (MRQ)
vs sector
0.00
13.18
Return on Investment (TTM)
vs sector
19.91
13.17
Return on Equity (TTM)
vs sector
20.13
15.10

EXECUTIVE LEADERSHIP

Yikui Li
Chairman of the Board, Since 2007
Salary: --
Bonus: --
Jun Ye Wang
Chief Accounting Officer, Secretary of the Board, Director, Since
Salary: --
Bonus: --
Cong Li
General Manager, Director, Since 2007
Salary: --
Bonus: --
Chung Sheng Leng
Deputy General Manager, Director, Since 2007
Salary: --
Bonus: --
Hong Chen
Deputy General Manager, Chief Engineer, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Dongbao New Village, Tonghua Cou
TONGHUA   JLN   134123

Phone: +86435.5088025
Site: www.thdb.com

TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.

SPONSORED STORIES